Financing ·
Aptevo Therapeutics registers up to $2.3M of common stock under ATM agreement
APVOAptevo Therapeutics Inc.
Aptevo Therapeutics filed a prospectus supplement to register an additional $2,309,834 in shares of common stock for sale under its existing At-The-Market (ATM) equity offering program with Roth Capital Partners. As of the filing date, the company had already sold 303,157 shares under this agreement, raising approximately $11.8 million in aggregate gross proceeds. This registration expands the total amount available for future sales under the current ATM facility. Aptevo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.